首页> 美国卫生研究院文献>Annals of the American Thoracic Society >Primary Ciliary Dyskinesia: First Health-related Quality-of-Life Measures for Pediatric Patients
【2h】

Primary Ciliary Dyskinesia: First Health-related Quality-of-Life Measures for Pediatric Patients

机译:原发性睫状运动障碍:首例与健康相关的生活质量衡量标准的小儿患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Rationale: Primary ciliary dyskinesia (PCD) is a rare disease. There are no available data on disease-specific pediatric patient–reported outcomes.>Objectives: Our objective was to create developmentally appropriate, health-related quality-of-life questionnaires (QOL-PCD) for children (6–12 yr) and adolescents (13–17 yr) with PCD and a parent proxy measure.>Methods: The QOL-PCD was developed using a cross-cultural protocol-driven approach satisfying both North American and European drug regulatory agency guidelines. A conceptual framework was generated by literature review, focus groups (expert clinicians and patients/parents), and open-ended interviews with children, adolescents, and parents of patients with PCD. We recruited participants from international research consortiums, PCD clinics, and patient advocacy groups, aiming for representation of a wide spectrum of disease severity, sociodemographic status, and ethnicity. Qualitative interviews were conducted by trained and experienced research assistants and psychologists. Transcripts were content-analyzed with Atlas.ti/NVivo to assess saturation of content. A self-completed item relevance survey was administered to E.U. participants. Qualitative and quantitative data were used to construct draft instruments. Questionnaires were further refined after cognitive interviews.>Measurements and Main Results: Focus groups (n = 62 experts; n = 20 patients/parents) and open-ended interviews with patients/parents (n = 69; 34 males; age at diagnosis, 0–15 yr; FEV1, 58–118% predicted) revealed a wide spectrum of issues unique to this population. Content analysis of transcripts identified the following domains, depending on age: Respiratory Symptoms, Physical Functioning, Emotional Functioning, Treatment Burden, Ears and Hearing, Sinus Symptoms, Social Functioning, Role Functioning, Vitality, Health Perceptions, School Functioning, and Eating and Weight. Various items were retained in questionnaires, based on age and role of respondent: 37, 43, and 41 items for children, adolescents, and parent proxy, respectively. The item relevance survey (n = 57) yielded results similar to those of open-ended interviews. Cognitive testing (n = 47; 20 males; age at diagnosis, 0–11 yr; FEV1, 49–124% predicted) confirmed that items and response choices were clear and understood by respondents, and that all relevant items were included.>Conclusions: The QOL-PCD measures, developed using rigorous, protocol-driven methods and international collaborations, have demonstrated content validity and cross-cultural equivalence for implementation in English-speaking populations. Psychometric testing is underway to determine their measurement properties for evaluating clinical interventions and informing quality of care.
机译:>原理:原发性睫状运动障碍(PCD)是一种罕见的疾病。目前尚无有关特定疾病的儿科患者报告的结局数据。>目标:我们的目标是为儿童创建与发育有关的,健康相关的生活质量调查表(QOL-PCD)(6 –12岁)和青少年(13–17岁)采用PCD和父母替代措施。>方法: QOL-PCD是使用跨文化协议驱动的方法开发的,满足了北美和欧洲药品监管机构指南。通过文献回顾,焦点小组(专家临床医生和患者/父母)以及对PCD患者的儿童,青少年和父母进行的不限成员名额访谈,形成了一个概念框架。我们从国际研究协会,PCD诊所和患者权益团体中招募了参与者,旨在代表各种疾病的严重程度,社会人口统计学状况和种族。定性的采访是由训练有素,经验丰富的研究助手和心理学家进行的。使用Atlas.ti / NVivo对成绩单进行内容分析,以评估内容的饱和度。对欧盟进行了一项自我完成的项目相关性调查。参与者。定性和定量数据被用于构建文书草案。 >测量和主要结果:焦点小组(n = 62位专家; n = 20位患者/父母)和不限成员名额的患者/父母访谈(n = 69; 34)男性;诊断年龄:0-15岁; FEV1,预测为58-118%)揭示了该人群独特的广泛问题。笔录的内容分析根据年龄确定了以下领域:呼吸系统症状,身体功能,情绪功能,治疗负担,耳朵和听力,窦性症状,社会功能,角色功能,生命力,健康认知,学校功能以及饮食和体重。根据受访者的年龄和角色,调查表中保留了各种项目:分别针对儿童,青少年和父母代用品的37、43和41个项目。项目相关性调查(n = 57)得出的结果与开放式访谈相似。认知测试(n = 47; 20名男性;诊断年龄为0-11岁; FEV1,预测为49-124%)证实受访者清楚并理解了项目和回答选择,并且包括了所有相关项目。 >结论:使用严格的,协议驱动的方法和国际合作开发的QOL-PCD措施已经证明了在英语人群中实施的内容有效性和跨文化等效性。心理测量测试正在进行中,以确定其测量属性,以评估临床干预措施并告知护理质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号